Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vicor

Top 3 Industrials Stocks That May Crash This Month

As of July 23, 2025, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket

Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results.

4 Stocks That Crushed Analyst Estimates by More Than Double

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

A Preview Of Vicor's Earnings

Vicor (NASDAQ:VICR) is set to give its latest quarterly earnings report on Thursday, 2022-04-21. Here's what investors need to know before the announcement. Analysts estimate that Vicor will report an earnings per share (EPS) of $0.27.

Here's How Much $100 Invested In Vicor 15 Years Ago Would Be Worth Today

Vicor (NASDAQ:VICR) has outperformed the market over the past 15 years by 5.26% on an annualized basis producing an average annual return of 13.2%. Currently, Vicor has a market capitalization of $2.83 billion.

Vicor: Q4 Earnings Insights

Vicor (NASDAQ:VICR) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Vicor missed estimated earnings by 55.56%, reporting an EPS of $0.2 versus an estimate of $0.45.

inkl

Read news from The Economist, FT, and more,
with one subscription

Organisations

the White House

Abbott Laboratories

Regeneron Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

314,371 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play